Burn trauma,especially extensive ones, remains a life-threatening local and general inflammatory condition destroying the skin and underlying tissues, and resulting in serious sequelae. Remarkable progress has been achieved during last 30 years，stem cell therapy plays an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation will be evaluated in patients with acute burn.
To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Acute, Moderate-Severe, Full-thickness burn.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Participants will be given conventional therapy plus hUCMSCs transplantation.
Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
Participants will be given conventional therapy only.
The Second Affiliated Hospital of Kunmming Medical College
Kunming, Yunnan, China
RECRUITINGThe ratio of wound contraction and re-epithelialisation
Time frame: 6 months after treatment
Complete healing time for investigated burn area
Time frame: 6 months after treatment
Vancouver Scar Scale
Time frame: 6 months after treatment
Incidence of infections and bleedings in burn wounds
Time frame: 6 months after treatment]
Engraftment assessment: Vitality of the graft
Time frame: 6 months after treatment]
McGill pain Questionnaire
Time frame: 6 months after treatment
Incidence of Adverse Events and Serious Adverse Events
Time frame: 6 months after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.